Literature DB >> 30354696

Understanding the role of exogenous boosting in modeling varicella vaccination.

Sandra E Talbird1, Elizabeth M La1, Josephine Mauskopf1, Alexandra Altland2, Vince Daniels2, Lara J Wolfson2.   

Abstract

INTRODUCTION: The exogenous boosting (EB) hypothesis posits that cell-mediated immunity is boosted for individuals reexposed to varicella-zoster virus (VZV). Historically, mathematical models of the impact of universal childhood varicella vaccination (UVV) have used limited data to capture EB and often conclude that UVV will temporarily increase herpes zoster (HZ) incidence. AREAS COVERED: We updated a 2013 systematic literature review of 40 studies to summarize new evidence from observational or modeling studies related to EB and its parameterization. We abstracted data on observational study designs and mathematical model structures, EB frameworks, and HZ-related parameter values. EXPERT COMMENTARY: This review identified an additional 41 studies: 22 observational and 19 modeling studies. Observational analyses generally reported pre-UVV increases in HZ incidence, making it difficult to attribute post-UVV increases to UVV versus other causes. Modeling studies considered a range of EB frameworks, from no boosting to full permanent immunity. Mathematical modeling efforts are needed in countries with long-standing vaccination programs to capture the dynamics of VZV transmission and temporal changes that may affect HZ incidence. Use of real-world pre-/postvaccination data on varicella and HZ incidence to validate model predictions may improve approaches to EB parameterization and understanding of the effects of varicella vaccination programs.

Entities:  

Keywords:  Varicella; chickenpox; exogenous boosting; herpes zoster; shingles; vaccination; vaccine

Mesh:

Substances:

Year:  2018        PMID: 30354696     DOI: 10.1080/14760584.2018.1538801

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  6 in total

1.  Routine varicella vaccination program and hospitalization for herpes zoster in Japan.

Authors:  Yasutaka Kuniyoshi; Haruka Tokutake; Natsuki Takahashi; Azusa Kamura; Sumie Yasuda; Makoto Tashiro
Journal:  Hum Vaccin Immunother       Date:  2021-10-06       Impact factor: 4.526

2.  Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.

Authors:  Lara J Wolfson; Vincent J Daniels; Matthew Pillsbury; Zafer Kurugöl; Cuneyt Yardimci; Jeffrey Kyle; Ener Cagri Dinleyici
Journal:  PLoS One       Date:  2019-08-13       Impact factor: 3.240

3.  Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.

Authors:  Ellen Wolff; Katarina Widgren; Gianpaolo Scalia Tomba; Adam Roth; Tiia Lep; Sören Andersson
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

4.  Economic burden of varicella in Europe in the absence of universal varicella vaccination.

Authors:  Manjiri Pawaskar; Estelle Méroc; Salome Samant; Elmira Flem; Goran Bencina; Margarita Riera-Montes; Ulrich Heininger
Journal:  BMC Public Health       Date:  2021-12-21       Impact factor: 3.295

Review 5.  Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review.

Authors:  Catherina X Pan; Michelle S Lee; Vinod E Nambudiri
Journal:  Ther Adv Vaccines Immunother       Date:  2022-03-21

6.  Clinical and economic impact of universal varicella vaccination in Norway: A modeling study.

Authors:  Manjiri Pawaskar; Colleen Burgess; Mathew Pillsbury; Torbjørn Wisløff; Elmira Flem
Journal:  PLoS One       Date:  2021-07-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.